Cellyan Biotechnology Co., Ltd filed a Form F-1 registration statement for an initial public offering on 2024-10-29. It has amended it 3 times. It filed its final prospectus on 2025-01-15, at a public offering price of $4.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
The Class A Ordinary Shares are listed on the Nasdaq Stock Market, or Nasdaq, under the symbol “HKPD.” On March 26, 2026, the last reported sale price of the Class A Ordinary Shares on Nasdaq was $0.65 per Class A Ordinary Share.From the F-1 filed 2026-03-27
Shares offered
This is the initial public offering of Hong Kong Pharma Digital Technology Holdings Limited, a Cayman Islands exempted holding company (“Hong Kong Pharma”) of 1,000,000 ordinary shares, par value $0.001 per share (the “Ordinary Shares”) on a firm commitment basis, which represents approximately 9.09% of the total outstanding Ordinary Shares following completion of this offering.From the 424B4 filed 2025-01-15
Offering price
The initial public offering price per Ordinary Share is $4.00.From the 424B4 filed 2025-01-15
Use of proceeds
We plan to use the net proceeds of this offering for (i) development and upgrade of our supply chain ERP systems, (ii) procurement of warehouse equipment, (iii) expansion of our sales and marketing team, and (iv) general working capital and for other general corporate purposes.From the 424B4 filed 2025-01-15
Revenue
Our total revenue was $16,688,364 for the fiscal year ended March 31, 2024, representing an increase of $4,132,373, or 33% from $12,555,991 for the fiscal year ended March 31, 2023.From the F-1/A filed 2024-12-10
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-10-29 | Registration statement filed (foreign issuer) | F-1 |
| 2024-11-21 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-11-27 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-12-10 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-01-15 | Final prospectus filed: the offering is priced | 424B4 |
| 2026-03-27 | Registration statement filed (foreign issuer) | F-1 |
Tools for this story
Each opens in a new tab, filled in for Cellyan Biotechnology Co., Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.